Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Palazestrant · OP-1250

Small molecule · Degrader of Estrogen receptor alpha (ESR1) · developed by Olema Pharmaceuticals

Phase 3 Most advanced trial
OLMA Developer
2 Registered trials

What is Palazestrant?

Palazestrant is an orally available small molecule that binds the ligand pocket of estrogen receptor alpha (ESR1), competing with estradiol, and acts as a selective estrogen receptor degrader that induces ERalpha degradation. It is being studied in breast cancer, including ER-positive, HER2-negative disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
OP-1250
Drug type
Small molecule
Targets
Estrogen receptor alpha (ESR1)
Mechanism
Degrader of Estrogen receptor alpha (ESR1)
Pathways
estrogen signaling, estrogen-driven transcription, ERalpha degradation
Therapy area
Oncology
Developer
Olema Pharmaceuticals, Inc. (OLMA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
VU35KM56Q4

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06016738 Phase 3 Breast Cancer Active not recruiting OLMA
NCT04505826 Phase 1/2 Hormone Receptor Positive Breast Carcinoma Completed OLMA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Breast CancerBreast CancerER Positive Breast CancerHER2 Negative Breast CarcinomaMetastatic Breast CancerHER2-negative Breast CancerHormone Receptor Positive Breast Carcinoma

Other drugs acting on ESR1

More from Olema Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OLMA page.

Follow OLMA, the company behind Palazestrant

See OLMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OLMA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.